Gene Biotherapeutics, Inc.
OTC: CRXM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher J. Reinhard
- Employees
- 3
- Headquarters
- San Diego, United States
- IPO year
- 2000
- Market cap
- $6.5K
- Website
- https://genebiotherapeutics.com
Loading CRXM…
Loading profile data…Frequently asked questions about CRXM
What does Gene Biotherapeutics, Inc. (CRXM) do?
Gene Biotherapeutics, Inc. is a biotechnology company in the clinical development stage, dedicated to researching and bringing to market angiogenic gene therapy treatments for cardiovascular conditions across the United States. Its primary investigational compound, Generx, an angiogenic gene therapy candidate, is currently undergoing Phase 3 cli...
Where does CRXM trade?
Gene Biotherapeutics, Inc. (CRXM) trades on the Other OTC.
What sector is CRXM in?
Gene Biotherapeutics, Inc. (CRXM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Gene Biotherapeutics, Inc.?
Christopher J. Reinhard is the chief executive officer of Gene Biotherapeutics, Inc. (CRXM).
Where is Gene Biotherapeutics, Inc. headquartered?
Gene Biotherapeutics, Inc. is headquartered in United States.
Does CRXM pay a dividend?
Gene Biotherapeutics, Inc. (CRXM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRXM go public?
Gene Biotherapeutics, Inc. (CRXM) completed its initial public offering in 2000.